Cobicistat
- Generic Name
- Cobicistat
- Brand Names
- Evotaz, Genvoya, Prezcobix, Rezolsta, Stribild, Tybost
- Drug Type
- Small Molecule
- Chemical Formula
- C40H53N7O5S2
- CAS Number
- 1004316-88-4
- Unique Ingredient Identifier
- LW2E03M5PG
- Background
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that ar...
- Indication
Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due...
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Fore Biotherapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT06385119
- Locations
- 🇺🇸
PPD - Austin Research Unit, Austin, Texas, United States
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-01-18
- Target Recruit Count
- 142
- Registration Number
- NCT06014489
- Locations
- 🇳🇱
NL-Leeuwarden-MCL, Leeuwarden, Netherlands
🇳🇱NL-Enschede-MST, Enschede, Netherlands
🇳🇱NL-Eindhoven-MAXIMAMC, Eindhoven, Netherlands
Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT05748093
- Locations
- 🇳🇱
MaastrichtUMC, Maastricht, Limburg, Netherlands
Electrophysiological Effects of Potential QT Prolonging Drugs
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 44
- Registration Number
- NCT05716854
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Fore Biotherapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05503797
- Locations
- 🇺🇸
Maryland Oncology Hematology- Columbia, Rockville, Maryland, United States
🇺🇸Taylor Cancer Research Center, Maumee, Ohio, United States
🇫🇷Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT05458102
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC., Long Beach, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT05236738
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 160
- Registration Number
- NCT05078671
- Locations
- 🇳🇱
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
🇳🇱Amsterdam Universitair Medische Centra, Amsterdam, Netherlands
🇳🇱Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT04718805
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04661397
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.